Charles River Laboratories and ENYO Pharma today announced results of a successful collaboration
(http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-newsArticle&ID=2318801)
Read next in 'Latest news'
- The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
- The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
- Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
- New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
- New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
Latest Press Release 